retatrutide type 2 diabetes trial results 2024 phase 2 Retatrutide: A Triple Agonist Shaping the Future of Metabolic Care ADA 2026: Retatrutide Revolution

Injection technique: Select an appropriate injection site: the abdomen (at least 5 cm from the navel) or the outer thigh are suitable for self-administration

Click [...] To view or add a comment, sign in $NVO has started a Phase 1 trial for its new obesity drug candidate LX9851, developed with Lexicon Pharmaceuticals The drug is oral and works differently from current GLP-1 treatments, targeting fat metabolism and satiety signals The study will assess safety in overweight and obese patients, with results expected in Q1 2027 Lexicon receives a $10M milestone payment and could earn up to $1B plus royalties if successful #stocks #Investing To view or add a comment, sign in 16,852 followers

DePetrocellis LVellaniVSchiano-MorielloAMariniPMagheriniPCOrlandoPet al

Those shortages of brand-name GLP-1s that Barkley mentions helped propel the growth of compounded GLP-1s at Ro and other telehealth companies -- but with the FDA having now declared GLP-1 shortages over, Ro is already done with selling compounded versions